Published in Antioxid Redox Signal on February 21, 2014
ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. J Mol Biol (1965) 46.35
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 19.56
Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science (1995) 12.94
Structure of 20S proteasome from yeast at 2.4 A resolution. Nature (1997) 12.73
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 11.62
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
A gated channel into the proteasome core particle. Nat Struct Biol (2000) 5.42
The proteasome: a suitable antineoplastic target. Nat Rev Cancer (2004) 5.22
Is allostery an intrinsic property of all dynamic proteins? Proteins (2004) 4.99
Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry. Mol Cell (2007) 4.54
Complete subunit architecture of the proteasome regulatory particle. Nature (2012) 4.41
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature (1993) 3.65
Quantitative dynamics and binding studies of the 20S proteasome by NMR. Nature (2007) 3.63
Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol (2008) 3.62
Proteasome from Thermoplasma acidophilum: a threonine protease. Science (1995) 3.62
The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure (2002) 3.44
Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci U S A (2012) 3.42
Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell Biol (2005) 3.38
Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett (1998) 3.32
mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol (2005) 3.24
Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell (2006) 3.21
The proteasome. Annu Rev Biophys Biomol Struct (1999) 3.13
Structural basis for the activation of 20S proteasomes by 11S regulators. Nature (2000) 3.04
Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities. Cell (2006) 2.87
ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell (2005) 2.82
Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A (1997) 2.81
Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol (2005) 2.73
The 1.9 A structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. Mol Cell (2005) 2.68
Light-activated DNA binding in a designed allosteric protein. Proc Natl Acad Sci U S A (2008) 2.67
Subunit interaction maps for the regulatory particle of the 26S proteasome and the COP9 signalosome. EMBO J (2001) 2.66
Characterization of the FKBP.rapamycin.FRB ternary complex. J Am Chem Soc (2005) 2.60
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem (2001) 2.58
Endoproteolytic activity of the proteasome. Science (2002) 2.56
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res (2011) 2.56
Nested cooperativity in the ATPase activity of the oligomeric chaperonin GroEL. Biochemistry (1995) 2.49
20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev (2007) 2.47
The origin of allosteric functional modulation: multiple pre-existing pathways. Structure (2009) 2.33
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature (2008) 2.22
Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol (2002) 2.17
PA200, a nuclear proteasome activator involved in DNA repair. EMBO J (2002) 2.15
Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem (2002) 2.08
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood (2009) 2.06
Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci U S A (1997) 1.99
Differential roles of the COOH termini of AAA subunits of PA700 (19 S regulator) in asymmetric assembly and activation of the 26 S proteasome. J Biol Chem (2008) 1.93
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Conformational switching of the 26S proteasome enables substrate degradation. Nat Struct Mol Biol (2013) 1.90
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood (2007) 1.89
Stability of the proteasome can be regulated allosterically through engagement of its proteolytic active sites. Nat Struct Mol Biol (2007) 1.89
Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell (2012) 1.83
Molecular machines for protein degradation. Chembiochem (2005) 1.81
Molecular model of the human 26S proteasome. Mol Cell (2012) 1.79
The HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core particle. Nat Struct Mol Biol (2005) 1.78
Allostery in disease and in drug discovery. Cell (2013) 1.77
4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem (1999) 1.74
Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J Neurochem (1980) 1.74
Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A (1998) 1.72
Dynamic regulation of archaeal proteasome gate opening as studied by TROSY NMR. Science (2010) 1.69
Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Natl Acad Sci U S A (2001) 1.58
Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem (1998) 1.57
ATP hydrolysis-dependent disassembly of the 26S proteasome is part of the catalytic cycle. Cell (2005) 1.55
Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol (2001) 1.52
Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol (1998) 1.51
Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. J Biol Chem (1997) 1.47
The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem (2003) 1.46
Imaging and manipulation of biological structures with the AFM. Micron (2002) 1.46
Structural studies of HIV-1 Tat protein. J Mol Biol (1995) 1.45
Structure of the human 26S proteasome: subunit radial displacements open the gate into the proteolytic core. J Biol Chem (2008) 1.43
Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. Biochem J (1998) 1.42
Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J Innate Immun (2012) 1.38
Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening. Mol Cell (2010) 1.36
LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol (2007) 1.35
Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell (2001) 1.34
Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings. J Biol Chem (2002) 1.32
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia (2011) 1.29
Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest (2000) 1.27
A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer (2006) 1.25
Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol (2001) 1.25
HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation. J Biol Chem (1997) 1.24
Proteasome plasticity. FEBS Lett (2005) 1.23
Proteasomal AAA-ATPases: structure and function. Biochim Biophys Acta (2011) 1.22
Functional analysis of the proteasome regulatory particle. Mol Biol Rep (1999) 1.18
Pituitary multicatalytic proteinase complex. Specificity of components and aspects of proteolytic activity. Biochemistry (1989) 1.17
ATP-induced structural transitions in PAN, the proteasome-regulatory ATPase complex in Archaea. J Biol Chem (2007) 1.15
HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol (2004) 1.13
Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits. FEBS Lett (2003) 1.12
Structure and allostery of the chaperonin GroEL. J Mol Biol (2012) 1.11
A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the alpha-ring channel. Structure (2009) 1.11
Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor. J Biol Chem (2008) 1.10
Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One (2011) 1.10
Proteasome allostery as a population shift between interchanging conformers. Proc Natl Acad Sci U S A (2012) 1.09
Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst (2010) 1.09
Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Biochim Biophys Acta (2011) 1.08
Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry (2003) 1.07
Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets (2011) 1.07
Point mutations and sequence variability in proteins: redistributions of preexisting populations. Proc Natl Acad Sci U S A (2001) 1.06
The central unit within the 19S regulatory particle of the proteasome. Nat Struct Mol Biol (2008) 1.82
Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry (2003) 1.07
Small-molecule inhibitors of proteasome activity. Methods Mol Biol (2005) 1.01
Molecular mechanisms of proteasome plasticity in aging. Mech Ageing Dev (2010) 0.95
DNA-looping by RXR tetramers permits transcriptional regulation "at a distance". J Mol Biol (2004) 0.94
The proteasome in health and disease. Curr Pharm Des (2013) 0.92
Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. Neurobiol Aging (2013) 0.89
Characterization of noncompetitive regulators of proteasome activity. Methods Enzymol (2005) 0.89
Atomic force microscopic analysis of the binding of the Schizosaccharomyces pombe origin recognition complex and the spOrc4 protein with origin DNA. Proc Natl Acad Sci U S A (2004) 0.89
The growth-suppressive function of the polycomb group protein polyhomeotic is mediated by polymerization of its sterile alpha motif (SAM) domain. J Biol Chem (2012) 0.88
AFM of biological complexes: what can we learn? Curr Opin Colloid Interface Sci (2008) 0.85
Atomic force microscopy of proteasome assemblies. Methods Mol Biol (2011) 0.81
Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design. Curr Med Chem (2006) 0.79
Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome. J Pept Sci (2014) 0.77
Highbrow proteasome in high-throughput technology. Expert Rev Proteomics (2006) 0.75
Atomic force microscopy as a tool to study the proteasome assemblies. Methods Cell Biol (2008) 0.75
Targeting Protein-Protein Interactions in the Proteasome Super-Assemblies. Curr Top Med Chem (2015) 0.75